For the quarter ending 2025-09-30, POAI had -$324,411 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss from continuing operations | -77,646,737 | -4,264,311 |
| Depreciation and amortization | 32,612 | 65,222 |
| Amortization of operating lease right-of-use assets | 141,982 | 271,099 |
| Non-cash write off of accounts payable and related accrued expenses | 0 | -676,678 |
| (gain) loss on derivative instruments | 74,366,000 | 0 |
| Vesting expense | 371,335 | 0 |
| Issuance of shares to non-employees | 133,333 | 66,667 |
| Loss on disposal of property and equipment | 0 | - |
| Accounts receivable | 3,052 | -11,197 |
| Inventories | -4,717 | -3,054 |
| Prepaid expense and other assets | 273,341 | 297,818 |
| Accounts payable | 1,371,226 | 511,791 |
| Accrued expenses and other | -7,701 | 371,361 |
| Contract liabilities | -2,500 | -75,000 |
| Operating lease liability | -141,739 | -267,216 |
| Other long-term liabilities | 0 | - |
| Net cash (used in) continuing operating activities | -1,653,865 | -4,280,632 |
| Purchase of property and equipment | 0 | 0 |
| Net cash (used in) continuing investing activities | 0 | 0 |
| Proceeds from issuance of common stock and warrants | 1,444,044 | 3,165,365 |
| Costs to issue common stock and warrants | 38,058 | 202,820 |
| Proceeds from issuance of financing note payable | 0 | 264,048 |
| Repayment of note payable | 76,674 | 0 |
| Net cash provided by continuing financing activities | 1,329,312 | 3,226,593 |
| Net cash provided by (used in) operating activities | 142 | 200,444 |
| Net cash provided by (used in) investing activities | 0 | 625,000 |
| Net cash provided by (used in) financing activities | 0 | 0 |
| Net cash provided by (used in) discontinued operations | 142 | 825,444 |
| Net (decrease) in cash | -324,411 | -228,595 |
Predictive Oncology Inc. (POAI)
Predictive Oncology Inc. (POAI)